Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, Rebecca Asher, Richard T. Penson, Amit M. Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedländer, Alessandra Baldoni, Tjoung‐Won Park‐Simon, Kenji Tamura, Gabe S. Sonke, Alla Lisyanskaya, Jae‐Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth Lowe, Philip Rowe, Ignace Vergote, Éric Pujade-Lauraine, The SOLO2/ENGOT-Ov21 Investigators
Abstract
(Abstracted from Lancet Oncol 2021;22:620–631) The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is approved as maintenance therapy in newly diagnosed ovarian cancer or in patients with platinum-sensitive, relapsed ovarian cancer regardless of BRCA1/2 mutation status. The primary analysis of the SOLO2/ENGOT-Ov21 phase 3 trial found a significant improvement in median progression-free survival associated with olaparib treatment compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.